6th-Generation Silicone Breast Implant Surgery: The Complete Surgeon’s Guide

Breast augmentation is consistently one of the most frequently performed cosmetic surgical procedures globally — and for good reason. For many women, the size, shape, or symmetry of their breasts is a source of genuine self-consciousness that affects daily choices, clothing decisions, and self-confidence in ways that are deeply personal and entirely valid. The surgical solution has improved steadily over six decades of innovation — from the first generation of silicone gel implants in the 1960s through increasingly refined generations addressing safety, feel, and durability.

The technology that Abmedi uses — sixth-generation silicone gel implants with nano-smooth surface technology and ergonomic shape-adaptive design — represents the current pinnacle of this evolution. FDA-approved in October 2024 and used internationally for over 14 years prior to US approval, these implants have an extensively documented clinical safety profile, including a capsular contracture rate of approximately 1% at three years compared to the industry average of around 10.6%. Published in Nature and the Aesthetic Surgery Journal, the clinical data supporting this technology is among the most robust in breast implant history.

This guide covers everything you need to understand about sixth-generation breast implant surgery at Abmedi: what makes this technology different, the implant options available, who is a good candidate, the surgical approach including placement options, recovery, risks, and how to approach the decision process with realistic, informed expectations.

 

What Makes 6th-Generation Silicone Implants Different?

The breast implant industry has evolved through six distinct generations since the 1960s. Each generation was defined by improvements in one or more aspects of the device — shell durability, gel cohesion, surface characteristics, or safety features. The sixth generation, which Abmedi uses exclusively for breast augmentation, introduces innovations across all of these dimensions simultaneously.

The clearest summary of what distinguishes sixth-generation technology from earlier implants: the device is engineered to behave like natural breast tissue, not merely to fill a space where breast tissue was absent. This distinction is more than marketing language — it has measurable clinical consequences for how implants feel, how they move, how they interact with surrounding tissue, and how long they remain complication-free.

FDA Approval Context Sixth-generation silicone gel implants received Premarket Approval (PMA) from the US Food and Drug Administration (FDA) in October 2024 for breast augmentation. This approval was the result of extensive US clinical trial data combined with over 14 years of international post-market surveillance data — one of the longest pre-approval safety datasets in breast implant history. The implants are indicated for breast augmentation in women aged 22 and older. They are also being studied for reconstruction indications under an FDA investigational device framework. Abmedi provides complete FDA indication documentation to all patients at consultation.

 

The Technology: What Each Feature Actually Does

Understanding the individual technologies within sixth-generation implants helps patients make genuinely informed decisions rather than being swept along by impressive-sounding terminology. Here is a clear breakdown of each innovation, what it consists of, and what it means for your outcome.

 

Technology	What It Is	Clinical Benefit
Nano-Smooth Surface Technology	Microscopically treated silicone surface at the nanoscale level — creates a soft, silk-like feel while being classified as smooth (not textured)	Reduces friction between implant and surrounding tissue; lowers capsular contracture risk; no BIA-ALCL cases reported; classified smooth by FDA
Progressive Gel Filling	High-cohesion silicone gel engineered to replicate the density and fluidity of natural breast tissue at body temperature	Implants feel soft and natural to touch; move like natural breast tissue; maintain shape without gel migration on rupture
Ergonomic Shape-Adaptive Design	Round shape at rest; forms a natural teardrop silhouette when upright; adapts to all body positions and movements	Natural appearance in all positions; eliminates the ’round ball’ appearance when standing; particularly valued in thin-tissue patients
Integrity Indicator Barrier Layer	Visually distinctive barrier layer surrounding the outer shell — visible pre-operatively as a color marker	Surgeon can confirm implant integrity before insertion; provides patients and surgeons with immediate quality verification
Unified Shell Architecture	Proprietary shell construction that links outer shell and inner gel into a single cohesive unit	Allows implant to pass through smaller incisions (some cases < 1 inch) without compromising structural integrity; enables minimally invasive techniques
RFID Safety Chip (Optional)	A miniature RFID micro-transponder embedded within the implant; readable with an external hand-held device	Non-invasive post-operative identification of implant model, size, and serial number without imaging; useful if implant card is lost or in emergency identification
6th-Generation Silicone Gel	Most advanced generation of cohesive silicone gel; used in clinical studies for 14+ years internationally before US FDA approval in 2024	Extensive international safety data; Nature-journal-published studies; FDA PMA approved September/October 2024

 

Why the Surface Matters: Nano-Smooth vs. Smooth vs. Textured

The surface of a breast implant is not a minor detail — it has significant implications for both safety and long-term comfort. Traditional smooth implants have a completely uniform, unmodified surface. Textured implants have a deliberately rough surface designed to allow tissue ingrowth and prevent rotation in shaped (teardrop) implants. Macro-textured implants — particularly the heavily textured varieties — have been associated with a rare but documented form of lymphoma called Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Sixth-generation implants used at Abmedi employ nano-surface technology — a microscopic surface treatment at such a fine scale that the implants are formally classified as smooth by the FDA. The nano-scale surface reduces friction between the implant and the surrounding capsule tissue, which published clinical data suggests is one mechanism contributing to the significantly lower capsular contracture rate. To date, no cases of BIA-ALCL have been reported in international datasets for this technology — an important safety distinction from both macro-textured implants and some earlier smooth implant generations.

The Ergonomic Design: Round vs. Adaptive Shape

Standard round silicone implants maintain the same round shape regardless of body position. This means that when a patient stands up, the implant projects uniformly — including in the upper pole, creating the characteristic look of a round implant that many patients specifically want to avoid. The ergonomic design used in Abmedi’s sixth-generation implants addresses this by engineering the gel filling to flow within the implant shell based on gravity. When the patient lies down, the implant assumes a rounded shape. When she stands, gravity causes the gel to settle downward, creating a naturally sloped upper contour — the teardrop silhouette that resembles natural breast tissue in the upright position. This adaptive behavior is unique to sixth-generation gel technology and is one of the reasons these implants consistently receive the highest patient satisfaction scores in peer-reviewed survey data.

 

6th-Generation vs. Traditional Implants: A Clinical Comparison

The table below draws on published data from Nahabedian et al. (2022), the Aesthetic Surgery Journal (2021), PRS Global Open (2022), and the pre-approval clinical studies submitted to the FDA.

 

	6th-Generation Silicone Implants (Abmedi)	Traditional Silicone Implants (Earlier Generations)
Capsular contracture rate	~1% at 3 years (clinical studies); <2% reported in PRS Global Open 2022	~10.6% industry average for traditional silicone implants (Nahabedian et al., 2022)
Surface classification	Classified smooth by FDA; nano-textured at microscopic level	Smooth or textured (macro-textured associated with BIA-ALCL risk)
BIA-ALCL risk	Zero cases reported in international clinical data to date	Associated with macro-textured implants; cases documented globally
Shape behavior	Round at rest; forms teardrop slope when upright; adapts to movement	Standard round implants maintain round shape regardless of position
Incision size	Some cases achieve insertion through < 1 inch incision (unified shell technology)	Standard incisions 1.5–2 inches typical for most silicone implants
Post-op identification	RFID chip allows external non-invasive identification	Reliant on surgical records or imaging (MRI/ultrasound)
Implant integrity indicator	Color-barrier layer provides pre-insertion visual integrity confirmation	No equivalent pre-insertion visual confirmation system
Clinical history	14+ years international use; FDA PMA approved October 2024	Longer US market history; extensive long-term US-specific data
Natural feel rating	Consistently rated ‘most natural’ in surgeon and patient surveys	Varies by generation; earlier generations often described as firmer
Subfascial suitability	Particularly suitable for subfascial placement in thin-tissue patients	Subfascial placement possible but less ideal for thinner gel formulations

 

The most clinically significant data point in this comparison is the capsular contracture rate. Capsular contracture — where the scar tissue capsule that normally forms around any implant tightens excessively — is the most common and most distressing complication of breast augmentation across all implant generations. Traditional smooth implants carry a published average rate of approximately 10.6%. The sixth-generation technology used at Abmedi has demonstrated rates below 2% in published peer-reviewed studies, and approximately 1% in the largest clinical series at three years. For a patient choosing between implant options, this difference represents a meaningful reduction in the likelihood of the most common reason women return to the operating room after breast augmentation.

 

Implant Types and Profiles: Choosing the Right Option

Abmedi offers sixth-generation silicone implants in two primary designs, each in multiple profiles. The choice between designs and profiles is determined by your anatomy, your existing breast tissue characteristics, your chest measurements, and your aesthetic goals.

Round Design

The round implant provides consistent, symmetrical fullness across the entire breast — upper and lower pole equally. It is the most commonly chosen design and appropriate for patients who want a more clearly augmented appearance with good upper pole fullness, or for those whose breast tissue is positioned lower on the chest wall where upper pole fullness is desired for proportional correction. Round implants also offer advantages in patients with mild asymmetry, as the symmetry of the round shape helps equalize minor differences.

Ergonomic (Adaptive-Shape) Design

The ergonomic design implant — using the progressive gel technology that adapts to gravity — provides a more naturally sloped appearance when upright. It is particularly appropriate for patients seeking the most natural-looking result, for women who have good existing breast tissue and primarily want refinement or enhancement rather than a dramatic augmentation, and for patients in whom the surgeon prefers subfascial placement. The natural behavior of this implant in different positions is particularly valued by patients who are concerned about the augmented look appearing artificial in certain clothing or activities.

An updated second-generation ergonomic implant incorporates further improved shell technology that increases the implant’s ability to fold and pass through even smaller incisions — making minimally invasive insertion approaches more routinely achievable.

Three Profiles: Mini, Demi, and Full

Both implant designs are available in three projection profiles. The profile determines how far the implant projects forward from the chest wall relative to its base diameter:

• Mini Profile: minimal projection for the base width; produces the most subtle, gentle enhancement. Appropriate for patients who want to feel proportionally larger within their frame without creating obvious augmentation
• Demi Profile: moderate projection; the most versatile option and the most commonly selected. Provides a balanced natural enhancement with clearly visible fullness
• Full Profile: maximum projection relative to base width; appropriate for patients desiring a more notable enhancement or whose existing breast tissue requires greater projection to achieve the desired silhouette

How Size Is Selected at Abmedi Cup size is an imprecise measure for implant selection — it varies between bra manufacturers and does not account for your chest width, skin stretch, or existing tissue. At Abmedi, implant sizing is determined by base width measurement of your natural breast, skin stretch assessment, tissue thickness, and 3D imaging simulation. We use physical implant sizers placed in a fitting bra during the consultation to provide a practical sense of the volume difference before any decision is made. We also use computer simulation imaging to show a projected outcome at different sizes. The goal is to reach a size that achieves your aesthetic goal while respecting the anatomical limits of your tissue — choosing too large an implant for your frame creates avoidable long-term complications.

 

Who Is a Good Candidate for Breast Augmentation with These Implants?

Sixth-generation silicone gel implants are FDA-indicated for breast augmentation in women aged 22 and older. Good candidates share these characteristics:

• Desire for breast size increase or improvement in breast shape, proportion, or symmetry for personal aesthetic reasons
• Breasts that have fully developed — minimum age 22 for silicone gel implants per FDA indication
• Good general health without active infection anywhere in the body at the time of surgery
• No untreated breast malignancy or pre-malignant condition
• Not currently pregnant or breastfeeding
• Adequate breast tissue to provide coverage of the implant — particularly relevant for subfascial (over-muscle) placement
• Realistic expectations: understanding that breast implants are not lifetime devices, that future replacement or removal surgery may be needed, and that the specific result cannot be precisely guaranteed
• Stable emotional and psychological health — the procedure should be driven by the patient’s own consistent, long-term wish, not by external pressure or a temporary change in circumstances

Candidates for Whom These Implants Are Particularly Suited

Sixth-generation technology is especially well-matched for:

• Patients who want the most natural-looking result — the ergonomic design’s adaptive behavior and nano-smooth surface produce results that are consistently described as ‘like natural tissue’ by both surgeons and patients
• Thin-tissue patients — patients with limited breast tissue who previously may have been advised only for submuscular placement can often achieve excellent results in the subfascial plane with sixth-generation implants, because the superior gel cohesion and surface technology reduce rippling and edge visibility
• Patients with a history of capsular contracture — the dramatically lower contracture rate makes these implants particularly appropriate for revision augmentation after capsular contracture with older generations
• Patients who want smaller incisions — the unified shell technology allows insertion through incisions as small as 2.5 cm in appropriate cases
• Patients who value long-term safety documentation — 14+ years of international data before US approval provides a track record that was not available for earlier generation implants at the time of their US launch

Important Contraindications Breast implant surgery with sixth-generation silicone implants is specifically contraindicated in patients with: active infection anywhere in the body; existing or suspected breast cancer or pre-cancer that has not received adequate treatment; current pregnancy; and breastfeeding. Additionally, patients with autoimmune conditions, connective tissue disorders, or significant systemic illnesses may be at higher risk for implant-related complications and require specialized assessment. These contraindications should be discussed completely and honestly at the pre-operative consultation.

 

Implant Placement: Submuscular, Subfascial, or Subglandular?

Where the implant is placed relative to the chest muscle and fascia is one of the most clinically significant decisions in breast augmentation planning. Sixth-generation implants are compatible with all three placement planes, and the choice is made based on the individual patient’s anatomy, tissue characteristics, and aesthetic goals.

Subglandular Placement (Over the Muscle)

The implant is placed between the breast gland and the pectoralis major muscle. This plane places the implant closest to the overlying breast tissue. Advantages: no muscle disruption means faster recovery; the natural breast mound is not affected by pectoralis contraction; no ‘animation deformity’ (the implant shifting with muscle contraction). Limitation: in patients with very limited breast tissue, the implant’s edges may be more visible or palpable. Subglandular placement is appropriate for patients with adequate natural breast tissue providing coverage.

Subfascial Placement (Under the Fascia, Over the Muscle)

The implant is placed between the deep fascia of the pectoralis muscle and the muscle itself — a specific anatomical plane that provides an additional layer of tissue coverage above the implant without entering the muscle. This is one of the most significant innovations enabled by sixth-generation implants specifically: their superior gel quality and nano-smooth surface make subfascial placement reliable in thinner patients who would previously have been directed to submuscular placement. Subfascial placement provides more coverage than subglandular while avoiding all of the disadvantages of muscle disruption, faster recovery than submuscular, and particularly natural results. At Abmedi, subfascial placement is our preferred approach for eligible patients — the results consistently look and feel most natural.

Submuscular Placement (Under the Muscle)

The implant is placed beneath the pectoralis major muscle. This has historically been the standard approach in the US since the 1990s for patients with limited tissue coverage, as the muscle provides substantial coverage of the implant. Advantages: maximum tissue coverage in very thin patients; excellent concealment of the upper implant edge. Disadvantages: greater disruption of the pectoralis muscle; more post-operative pain; longer recovery; risk of animation deformity (implants shift when the muscle is flexed — a visible and sometimes socially embarrassing consequence); and the muscle can push the implant downward or laterally over time. With the availability of sixth-generation implants, many patients who would previously have needed submuscular placement can now achieve excellent results with subfascial technique.

Surgeon’s Note on Placement Selection at Abmedi The choice between placement planes is not one-size-fits-all, and I am cautious of any surgeon who routinely places all implants in the same plane regardless of patient anatomy. At Abmedi, the placement decision is made after measuring tissue coverage with a ‘pinch test’ at the upper pole — if there is 2 cm or more of tissue, subfascial placement is typically very suitable. If tissue is limited, submuscular remains the safer option for adequate coverage. The most important outcome measure is a result that looks natural, feels natural, and remains durable over the long term — not adherence to any single placement philosophy.

 

Incision Options

Sixth-generation implants can be inserted through several incision approaches, with the optimal choice based on the patient’s anatomy, the implant size selected, and the surgeon’s technique.

• Inframammary fold (IMF): the most commonly used approach worldwide. The incision is made in the natural crease beneath the breast where it meets the chest wall. This crease conceals the scar naturally when wearing clothing or a bra. The IMF approach provides excellent surgical access for all placement planes and all implant sizes. Average incision length with sixth-generation implants: approximately 2.5–3 cm (1 inch) or less — meaningfully smaller than many traditional implant insertions due to the unified shell technology
• Periareolar: incision made along the lower edge of the areola. The scar blends with the pigment transition of the areola-skin junction. Suitable for patients with larger areolas providing adequate incision length. Slightly higher theoretical infection risk due to proximity to breast ducts
• Transaxillary (armpit): incision made in the axillary fold — the natural crease of the armpit. No incision on the breast itself. Requires an endoscope and specialized instrumentation. Used by surgeons experienced with endoscopic breast augmentation technique

At Abmedi, the inframammary fold incision is our standard approach for the majority of cases — it provides the best surgical access, the most reliable implant placement, and, with sixth-generation implant technology enabling smaller incisions, a scar that is typically imperceptible within 6–12 months.

 

The Pre-Operative Consultation at Abmedi

Every breast augmentation consultation at Abmedi is unhurried and thorough. This is not a procedure where decisions should be rushed. The consultation includes:

• Comprehensive medical and surgical history review including prior breast procedures, family history of breast cancer, current medications, and any autoimmune or connective tissue conditions
• Breast examination: assessment of tissue quality and thickness, existing ptosis (sag), asymmetry, nipple position, areola size, and inframammary fold position
• Precise measurement-based sizing: chest width, breast base diameter, tissue thickness ‘pinch test,’ skin stretch assessment
• Implant sizer fitting: physical implant sizers placed in a soft bra to demonstrate the volume change before any surgical plan is finalized
• 3D imaging simulation: computer-generated visualization of the projected result at different implant sizes — a communication tool, not a guarantee, but highly valuable for aligning expectations
• Placement discussion: explaining the advantages and trade-offs of subfascial vs. submuscular placement for the specific anatomy
• Implant design selection: round vs. ergonomic adaptive design; profile selection
• Incision planning: IMF, periareolar, or transaxillary — based on anatomy and preference
• Complete risk discussion: all risks documented in FDA labeling and published clinical literature are reviewed with every patient
• Warranty and follow-up plan: sixth-generation implants come with warranty programs; we register all implants and schedule FDA-recommended follow-up imaging

 

Pre-Operative Preparation

• Stop smoking at least four weeks before surgery — nicotine restricts blood flow to healing tissue and significantly increases infection and wound complication rates in breast surgery
• Discontinue blood-thinning medications and supplements 10–14 days before surgery: aspirin, ibuprofen, fish oil, vitamin E, ginkgo biloba, garlic, St. John’s Wort
• Anticoagulants (warfarin, rivaroxaban, clopidogrel): pause only under coordination with your prescribing physician
• Avoid alcohol 72 hours before surgery
• Do not apply lotions, creams, or deodorant to the breast or axillary area on the day of surgery
• Wear comfortable, loose front-opening clothing to your appointment — you will not be able to lift your arms above your head immediately after surgery
• Arrange a responsible adult driver and companion for at least 24–48 hours post-operatively
• Prepare your recovery space: reclining sleeping position (two to three pillows), front-closure sports bra, prescribed medications ready

 

What Happens During the Procedure

Breast augmentation with sixth-generation silicone implants at Abmedi is performed as a day surgery procedure under general anesthesia. Total operating time is typically 1–2 hours for a primary augmentation. The surgical sequence for the standard inframammary fold, subfascial approach:

• General anesthesia is administered; patient is positioned supine with arms slightly extended
• The breast and chest area is prepared with antiseptic solution; sterile draping applied
• A ‘no-touch technique’ is used — the implant is inserted with specialized insertion equipment that minimizes direct contact between the implant and the patient’s skin, reducing biofilm contamination risk. This is particularly important with modern smooth implants
• The inframammary fold incision is made precisely at the planned location; typically 2.5 cm in length or less
• The pocket is created in the subfascial plane (or submuscular if indicated) using electrocautery and blunt dissection; the pocket size is sized to the implant’s base diameter — precise pocket sizing is one of the most critical steps for long-term implant stability
• Before insertion, the integrity indicator barrier layer of the implant is visually confirmed under the operating room light — confirming shell integrity prior to placement
• The implant is loaded into an atraumatic insertion funnel and advanced into the pocket without direct hand contact
• Pocket position and implant height are assessed with the patient semi-upright; any asymmetry is corrected before closure
• The pocket is closed in layers with absorbable sutures; the skin is closed with a buried absorbable suture for a scar-free surface closure

 

Recovery After Breast Augmentation Surgery

Days 1–3: Rest and Compression

Waking from anesthesia, the breasts will feel tight, full, and high-sitting — exactly as expected. A post-surgical bra or soft compression garment is placed in the operating room and remains on throughout the first few days. Most patients describe the discomfort as significant tightness and pressure rather than sharp pain. This is most prominent in submuscular cases where the muscle has been elevated; subfascial cases typically involve meaningfully less discomfort. Prescribed pain medication is taken for the first 2–3 days as needed. No arms above the head, no pushing or pulling, no driving.

Days 4–10: Increasing Comfort and Mobility

By day three or four, most patients transition from prescription to over-the-counter pain management. Swelling of the breasts is prominent and the implants will sit higher than their final position — this is normal and expected. The incision is assessed at a post-operative visit around day 5–7 and covered with waterproof dressings; showering is permitted from day one in most cases with the drains covered. Walking and light daily activities at home are encouraged from day two.

Weeks 2–4: Back to Daily Life

Most patients with desk-based jobs return to work between days 5–10. The post-surgical bra is continued for 4–6 weeks. Arm movement normalizes progressively. Light exercise (walking, stationary cycling) is typically cleared at week 2–3; upper body exercise, heavy lifting, and sports wait until week 4–6 with surgeon clearance. The implants will still be positioned higher than their final position — ‘dropping and fluffing’ (the gradual settling of the implant into the pocket and softening of the overlying tissue) continues over several months.

Months 2–6: Final Result

The majority of swelling has resolved by 6–8 weeks, and the implants have begun settling into their final position. By three to six months, the ‘dropping and fluffing’ process is essentially complete — the implants are in their intended position, the overlying tissue has relaxed, and the result is fully visible. This is when formal outcome photography is conducted at Abmedi. The natural-looking result of the ergonomic design is most apparent at this stage — the breast takes on a natural slope and contour that is most apparent in the upright position.

Recovery Timeline Summary Days 1–3: Rest, compression bra, limited mobility. Days 4–10: Increasing activity, post-op visit, return to desk work. Week 2–3: Light exercise cleared; most social activity resumed. Week 4–6: Full exercise clearance; sports bra continued. Months 2–6: Implant settling complete; final result visible and documented.

 

Risks and Complications

Breast implant surgery carries specific risks that every patient must understand completely before proceeding. The FDA requires that these risks be disclosed in detail, and Abmedi supplements the FDA labeling with our own thorough informed consent discussion.

Primary Implant-Related Risks

• Capsular contracture: the most common complication of breast augmentation — tightening of the scar tissue capsule around the implant, causing firmness, asymmetry, or pain. Published rate for sixth-generation implants: approximately 1% at 3 years, compared to a traditional implant average of approximately 10.6%. Treatment in severe cases requires surgical removal of the capsule
• Implant rupture: all silicone gel implants can rupture over time. A ruptured sixth-generation silicone implant typically does not deflate visibly because the cohesive gel holds its shape (a ‘silent rupture’). FDA recommends MRI screening at 5–6 years post-implantation and every 2–3 years thereafter to assess implant integrity. The RFID chip in these implants does not detect rupture — it provides implant identification only
• Implant displacement or malposition: the implant shifts from its intended position — downward (bottoming out), outward (lateral displacement), or asymmetric between sides. Prevented by precise pocket sizing and proper post-operative bra support
• Infection: rare but serious. Sixth-generation implants are particularly vulnerable to biofilm formation in the early post-operative period before the capsule forms; the no-touch insertion technique is one of the primary risk-reduction strategies
• Changes in nipple or breast sensation: temporary or permanent changes in sensation occur in some patients; more common with periareolar incisions. Usually temporary but can be permanent
• Breast Implant Illness (BII): a term used by some patients to describe a constellation of systemic symptoms (fatigue, joint pain, cognitive symptoms) they associate with their breast implants. The medical and scientific literature has not established a proven causal link, but the FDA acknowledges patient reports and recommends that surgeons and patients be informed. At Abmedi, we have an open, non-dismissive discussion of BII with every patient who raises the topic

BIA-ALCL: What Patients Need to Know

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare type of lymphoma associated primarily with macro-textured breast implants. It is not a cancer of the breast tissue itself — it typically presents as a fluid collection or mass around the implant capsule, usually years after implantation. BIA-ALCL is treatable and often curable with capsule removal when detected early.

For sixth-generation nano-smooth implants: to date, no cases of BIA-ALCL have been reported in the international clinical dataset. The nano-smooth surface classification means these implants do not carry the surface roughness associated with macro-textured implant BIA-ALCL risk. This is an important safety distinction. Patients should nonetheless remain aware of BIA-ALCL as part of general breast implant education, and report any unexplained swelling around the implant to their surgeon.

FDA Warning: Breast Implants Are Not Lifetime Devices The FDA is explicit: breast implants are not permanent and will likely require replacement or removal during a patient’s lifetime. The longer an implant is in place, the greater the likelihood of complications requiring surgical management. Abmedi recommends MRI screening beginning at 5–6 years post-implantation (for silicone implants) and continuing every 2–3 years thereafter. Regular clinical examination by a board-certified plastic surgeon is also recommended annually. Patients should also perform regular breast self-examinations and maintain routine mammography screening as per their gynecologist’s recommendation.

 

Warranty and Long-Term Coverage

Sixth-generation implants used at Abmedi are accompanied by a comprehensive warranty program registered to each individual patient. Coverage options include:

• Standard warranty program: covers implant replacement in the event of confirmed device defect or rupture for a defined period following surgery; surgical and facility fees for replacement are covered to specified limits
• Enhanced protection program (optional registration): extends coverage for additional years and increases the financial protection for surgical fees; particularly recommended for patients who wish maximum long-term protection
• Lifetime capsular contracture coverage: unique to this implant generation — certain coverage programs include financial protection against implant replacement for capsular contracture for the lifetime of the device
• After 10 years, coverage continues with modified financial limits as documented in the warranty terms

At Abmedi, we register every implant on behalf of the patient at the time of surgery. Patients receive their implant identification card — showing implant serial number, model, and size — and are encouraged to keep this card securely. The RFID chip embedded in the implant serves as a backup identification system that remains with the patient regardless of what happens to paperwork over the years.

 

Cost of Breast Augmentation at Abmedi

Breast augmentation pricing at Abmedi is discussed transparently during the consultation. As a United States market reference, breast augmentation with sixth-generation silicone implants typically ranges from $7,000 to $15,000 depending on the implant size and type selected, the surgical approach, anesthesia fees, and whether concurrent procedures are planned. Sixth-generation implants carry a modestly higher device cost than earlier generation implants — this reflects the additional manufacturing technology — and this is included in our transparent pricing discussion.

Breast augmentation is an elective cosmetic procedure and is not covered by health insurance in the majority of cases. Exceptions may exist for breast reconstruction following mastectomy. Financing options are available at Abmedi for eligible patients through vetted healthcare financing partners.

 

Frequently Asked Questions

What makes sixth-generation implants better than what was available before?

Three primary advances: the capsular contracture rate (~1% vs. ~10.6% for traditional implants), the ergonomic shape-adaptive behavior that produces the most natural appearance in all positions, and the integrated safety features including the integrity indicator barrier and optional RFID chip. Additionally, the nano-smooth surface eliminates the BIA-ALCL risk associated with macro-textured implants while still providing the reduced-friction benefits of a modified surface. These are not incremental improvements — they represent meaningful clinical advantages that directly affect patient experience and safety outcomes.

Are these implants safe for patients with limited breast tissue?

Yes — and this is actually one of the specific advantages of sixth-generation implants. Patients who were previously told they were ‘too thin for implants over the muscle’ can often achieve excellent, natural results with subfascial placement using these implants, because the superior gel cohesion, nano-smooth surface, and unified shell technology reduce rippling and edge visibility. The subfascial placement avoids muscle disruption entirely, producing faster recovery and more natural movement. Each patient’s tissue thickness is measured during the consultation to determine the appropriate placement plane.

What is the RFID chip and is it required?

The RFID micro-transponder is an optional embedded technology that allows your implant to be identified non-invasively using an external hand-held reader, similar to a product scanner. It does not emit any signal on its own and cannot be activated without the external reader. It does not interact with airport security systems, MRI machines, or medical equipment. The chip contains information about the implant model, size, and serial number — useful if implant records are ever lost or if identification is needed in an emergency. It is not required as part of the standard implant, and patients who prefer not to have the chip can select implants without it.

Will my breasts still look and feel natural for activities like exercise?

The ergonomic adaptive design is specifically engineered for this concern. Because the gel flows with gravity and body position, the implants behave like natural breast tissue during movement — settling during upright exercise rather than maintaining a fixed round shape. Patients consistently report that these implants feel and move indistinguishably from natural tissue in daily activities, exercise, and intimate settings. The subfascial placement further enhances natural movement by preserving full pectoralis muscle function.

When should I have my implants checked?

The FDA recommends your first MRI screening at 5–6 years post-implantation for silicone gel implants, followed by repeat imaging every 2–3 years. Annual clinical examination by a plastic surgeon is recommended. Patients should also continue routine mammography screening — technicians should be informed that implants are present, as they use modified compression techniques. The RFID chip can assist in providing implant details to any healthcare provider who performs imaging. If you ever notice unexplained swelling, firmness, or change in breast shape between scheduled appointments, contact Abmedi promptly for evaluation.

 

 

Sixth-generation silicone breast implant technology represents the most significant advancement in the field in decades. The combination of dramatically lower capsular contracture rates, ergonomic shape-adaptive behavior, safety innovations, and extensive international clinical validation gives patients and surgeons a genuinely superior tool for breast augmentation. If you are considering breast augmentation, the most important step is a consultation where your individual anatomy is assessed carefully, your goals are understood clearly, and the full picture of risks, options, and realistic expectations is discussed honestly. That is the standard we hold ourselves to at Abmedi — and it is the minimum you should expect from any surgeon you consider for this procedure.

— Abmedi Breast Surgery Team

This article is for educational purposes only and does not substitute for an in-person consultation with a qualified board-certified plastic surgeon. For complete FDA safety information on silicone breast implants, visit www.fda.gov.